Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11119178 | 0.76 | — | — | |
| SCHEMBL3117371 | 0.76 | — | — | |
| SCHEMBL5502385 | 0.71 | SLC6A3 (0.42) | TSHR | |
| SCHEMBL5765094 | 0.71 | SLC6A3 (0.42) | TSHR | |
| SCHEMBL28400172 | 0.71 | — | — | |
| SCHEMBL2916786 | 0.69 | — | — | |
| SCHEMBL5496016 | 0.69 | SLC6A3 (0.49) | TSHR | |
| SCHEMBL4002689 | 0.69 | CPN1 (0.32) | GABRA1GABRA5GABRB2GABRR1GABRA4 | |
| Hydrochloric Acid SCHEMBL336871 | 0.69 | SLC6A3 (0.41) | TSHR | |
| SCHEMBL25859924 | 0.69 | SLC6A3 (0.49) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | GABRA1 2414/4885GABRA5 2263/4885GABRB2 2357/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | GABRA1 2974/4885GABRA5 1691/4885GABRB2 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.